What is William Blair's Forecast for CNTX FY2025 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Stock analysts at William Blair upped their FY2025 EPS estimates for shares of Context Therapeutics in a research note issued to investors on Wednesday, May 7th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of ($0.24) for the year, up from their prior forecast of ($0.26). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics' Q4 2025 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at ($0.50) EPS.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.05).

CNTX has been the subject of several other research reports. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. D. Boral Capital reissued a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Thursday, May 8th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $5.40.

Context Therapeutics Stock Down 3.7%

CNTX traded down $0.03 during mid-day trading on Monday, reaching $0.79. 79,300 shares of the company traded hands, compared to its average volume of 291,294. The company's fifty day moving average price is $0.78 and its 200-day moving average price is $1.10. The stock has a market capitalization of $70.87 million, a P/E ratio of -0.87 and a beta of 2.11. Context Therapeutics has a 52-week low of $0.55 and a 52-week high of $2.75.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds have recently modified their holdings of CNTX. Marshall Wace LLP bought a new position in Context Therapeutics in the 4th quarter worth $213,000. Renaissance Technologies LLC increased its position in Context Therapeutics by 412.8% in the fourth quarter. Renaissance Technologies LLC now owns 338,435 shares of the company's stock worth $355,000 after buying an additional 272,435 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Context Therapeutics by 9.2% in the fourth quarter. Geode Capital Management LLC now owns 628,729 shares of the company's stock worth $661,000 after buying an additional 52,830 shares during the period. Franklin Resources Inc. bought a new position in shares of Context Therapeutics in the third quarter worth about $3,689,000. Finally, Allostery Investments LP purchased a new position in shares of Context Therapeutics during the 4th quarter valued at about $998,000. Institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.